|Bid||44.79 x 800|
|Ask||44.80 x 800|
|Day's Range||44.56 - 45.06|
|52 Week Range||37.47 - 48.82|
|Beta (3Y Monthly)||0.95|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Company to host timely educational panel on breast density featuring leading clinicians
Hologic, Inc. (HOLX) will showcase its growing breast surgery franchise, which includes products such as the new Trident® HD specimen radiography system, LOCalizer™ wire-free guidance system and the BioZorb® marker, in Booth #103 at the 20th Annual Meeting of The American Society of Breast Surgeons (ASBS) in Dallas from April 30 to May 5. The pioneer behind the Genius™ 3D Mammography™ exam, Hologic has recently expanded its product portfolio significantly through insight-driven innovation and strategic acquisitions to address the entire clinical continuum of breast cancer diagnosis and care.
The Trident products are the only specimen radiographs on the market to use amorphous selenium direct capture imaging – the same detector technology used in Hologic’s 3Dimensions™ mammography system – to generate crisp, clear, high-resolution images. “The Trident HD system is a breakthrough solution that delivers the superior image quality clinicians have come to expect from Hologic products, helping to streamline workflows and reduce recalls while decreasing procedure times,” said Pete Valenti, Hologic’s Division President, Breast and Skeletal Health Solutions.
Cynosure launches “Be strong. Hologic’s (Nasdaq: HOLX) Cynosure division announced today that iconic actress, model, Broadway star and author Brooke Shields will serve as national spokesperson for the state-of-the-art SculpSure® body contouring laser treatment. Be confident.” campaign, Shields will inspire consumers to live confidently in a body that reflects their hard work and commitment to a healthy lifestyle.
Hologic, Inc. announced today that the Company plans to release its financial results for the second quarter of fiscal 2019 on Wednesday, May 1, 2019, after the market closes.
Proposed rule highlights the risks of breast density and emphasizes important advances in mammography technology, including 3D mammography
Hologic, Inc. (HOLX), an innovative medical technology company focused on improving women’s health and well-being through early detection and treatment, today opened its first Learning and Experience Centre in Zaventem, Belgium (a municipality neighboring Brussels). The state-of-the-art facility provides comprehensive training for customers, healthcare professionals and employees across Hologic’s Europe, Middle East and Africa (EMEA) region, centralizing the education experience for Hologic’s technologies.
NEW YORK, March 05, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Hologic, Inc. (HOLX) announced today that it has received a CE mark in Europe for its Omni™ hysteroscope, an innovative three-in-one modular scope with advanced visualization capabilities designed for both diagnostic and therapeutic hysteroscopic procedures. Obstetricians and gynecologists (ObGyns) can use the new Omni hysteroscope in out- and in-patient settings. “Experts agree that direct visualization of the uterine cavity in women with abnormal uterine bleeding is the gold standard that allows ObGyns to accurately identify and collect quality samples and remove pathology – in a safer and more effective manner than blind biopsy and curettage,”1 said Edward Evantash, M.D., Medical Director and Vice President of Global Medical Affairs, Hologic.
Hologic, Inc. (HOLX) announced today that its Aptima® HIV-1 Quant Dx Assay has received two new CE marks in Europe – for early infant diagnosis (EID) and for testing dried blood spots (DBS). This means the assay can be used to qualitatively detect HIV-1 RNA as an aid in the diagnosis of HIV-1 infected infants under 18 months old, and to test an additional sample type (DBS) to monitor viral load and disease progression in HIV-1 infected individuals in European and African countries. It is the first and only dual-claim assay for both viral load and early infant diagnosis.
-- FDA clearance makes clinically validated assay available for sexually-transmitted infection listed as emerging threat by the CDC --
NEW YORK, Jan. 17, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Hologic, Inc. announced today that the Company plans to release its financial results for the first quarter of fiscal 2019 on Wednesday, January 30, 2019, after the market closes.
Hologic, Inc. (HOLX) announced today preliminary revenue results for its first fiscal quarter ended December 29, 2018. The Company expects to report total revenues of approximately $831 million, an increase of 5% compared to the prior year period, or 5.7% in constant currency.
Hologic, Inc. announced today that the Company will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Tuesday, January 8, 2019 at 11:30 a.m.
Hologic, Inc.’s (Nasdaq: HOLX) Cynosure division announced today the North American launch of the FDA-cleared TempSure™ Surgical RF technology, a new offering of the TempSure™ radiofrequency (RF) platform that provides clinicians the ability to perform both surgical and non-surgical aesthetic procedures across a variety of specialties, on a single device. Cynosure also has returned TempSure™ Vitalia hand pieces and probes to the market and will continue to market its MonaLisa Touch® CO2 laser following the U.S. Food and Drug Administration (FDA) inquiry on products used in energy-based women’s health procedures.
Hologic, Inc. (HOLX) announced today that a Massachusetts Superior Court granted a preliminary injunction in lawsuits against Chinese X-ray equipment provider Direct Digital Imaging Technology (Beijing), Inc. (DDIT) and a former Hologic employee, Lawrence Ibbetson, for alleged misappropriation of trade secrets. Hologic alleges that DDIT and Ibbetson misappropriated trade secrets for selenium coating technology used in the detectors within Hologic's Selenia® Dimensions® and 3Dimensions™ mammography systems.
NEW YORK, Dec. 12, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Flexible, modular design with powerful visualization gives doctors a single device with three sheath options to both diagnose and treat patients
Hologic, Inc. (HOLX) will showcase its expanding suite of breast and skeletal health products, including screening, interventional, ultrasound and surgical solutions, in Booth #2511 at the 104th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) at McCormick Place in Chicago from Nov. 25 to 29. The pioneer behind the Genius™ 3D Mammography™ exam, Hologic has expanded significantly in recent years to offer innovations across the entire clinical continuum of breast health. In addition, two recent acquisitions of Faxitron® Bioptics, a leader in digital specimen radiography, and Focal Therapeutics, manufacturer of the BioZorb® marker, have enabled Hologic to play a larger role in breast conserving surgery and strengthened its offerings to radiologists, pathologists and breast surgeons.
Hologic, Inc. (HOLX) announced today that Ludwig N. Hantson has been elected to the Company’s Board of Directors, effective immediately. Dr. Hantson, who has more than 30 years of experience in the life sciences industry, is the Chief Executive Officer of Alexion Pharmaceuticals, Inc., a publicly-traded global biopharmaceutical company. Before joining Alexion, Dr. Hantson was President and Chief Executive Officer of Baxalta Incorporated.